Fig. 2
From: Targeting KRAS mutant cancers: from druggable therapy to drug resistance
Structures of KRAS surfaces targeted by KRAS mutant inhibitors. a Switch-II pocket (purple) of KRAS (G12C) bound to AMG510 (PDB: 6OIM). b MRTX1133 with KRAS G12D/GDP (PDB: 7RPZ)